Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections
Status:
Completed
Trial end date:
2020-12-14
Target enrollment:
Participant gender:
Summary
TEMO-CARB is a phase 3, randomized, controlled, multicentre, open-label pragmatic clinical
trial to test the non-inferiority of temocillin versus carbapenem as initial intravenous
treatment of Urinary Tract Infection (UTI) due to extended-spectrum beta-lactamase (ESBL)
producing enterobacteriaceae.
Phase:
Phase 3
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborators:
French National Network of Clinical Research in Infectious Diseases (RENARCI) Groupe Hospitalier Paris Saint Joseph